Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
6 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
The EU approved Enhertu (trastuzumab deruxtecan) as adjuvant monotherapy for adults with resected HER2-positive early breast cancer and residual invasive disease after neoadjuvant treatment.
The EU approved Enhertu for HER2-positive early breast cancer.
The EU approved Enhertu as adjuvant treatment for patients with residual disease after neoadjuvant treatment for HER2-positive early breast cancer.
AstraZeneca and Daiichi Sankyo's Enhertu has been recommended for approval in the EU as a treatment for adult patients with resected HER2-positive breast cancer who have residual disease after neoadjuvant treatment. The CHMP based its opinion on the DESTINY-Breast05 trial, which showed Enhertu reduced the risk of invas
HUTCHMED (China) (NASDAQ: HCM ) released quarterly financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you APIs. For real-time access to our entire catalog, please visit for a consultation. The full earnings call is available at Summary HUTCHMED (
On Monday, AstraZeneca (NASDAQ: AZN ) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered APIs. For comprehensive financial data and transcripts, visit View the webcast at Summary AstraZeneca reported a 6% growth in total revenue for the fi